

## CURRICULUM VITAE

NAME: Richard L. Edelson, MD

EDUCATION: 1962-1966 BA Hamilton College  
Major: Chemistry  
Minor: British and American Public Address

1966-1970 MD Yale University School of Medicine

CAREER: 1970-1971 Intern - (Internal Medicine)  
University of Chicago

1971-1972 Resident - (Dermatology)  
Massachusetts General Hospital

1972-1975 Research Associate, Laboratory of Immunology,  
National Institute of Allergy & Infectious Diseases  
National Institutes of Health

1975-1976 Senior Resident in Dermatology  
Columbia-Presbyterian Hospital

1976-1978 Assistant Professor of Dermatology  
Columbia College of Physicians and Surgeons

1978-1980 Associate Professor of Dermatology  
Columbia College of Physicians and Surgeons

1980-1985 Associate Director  
Columbia-Presbyterian General Clinical  
Research Center

1980-1985 Professor and Director of Research  
Department of Dermatology  
Columbia College of Physicians and Surgeons

Jan. 1986 - Present Professor and Chairman  
Department of Dermatology  
Yale University School of Medicine

November 2000 - 2003 Deputy Dean for Clinical Affairs  
Yale School of Medicine

July 2003 - Present Director, Yale Comprehensive Cancer Center  
Yale School of Medicine

### BOARD CERTIFICATION:

American Board of Dermatology

### MAJOR RESEARCH INTERESTS:

Immunology of Cutaneous T-Cell Lymphoma  
Clinical Investigation of Autoimmune Disorders  
Epidermal T-Cell Interactions  
Extracorporeal Photochemotherapy

LEADERSHIP: YALE MEDICAL CENTER COMMITTEES:

Chair, Search Committee for Chief of Medical Oncology  
Chair, Search Committee for Chairman of Internal Medicine  
Chair, Search Committee for Yale-New Haven Hospital Chief of Staff  
Chair, Search Committee for Faculty Practice COO  
Chair, Search Committee for Yale Cancer Center Director  
Member, Board of Trustees, Yale-New Haven Hospital  
President's Council, Yale-New Haven Hospital  
Steering Committee, Faculty Practice Plan  
Faculty Representative, Yale-New Haven Hospital Budget & Finance Committee  
Steering Committee - Graduate Program in Investigative Medicine 1999 -  
Committee on Emergency Medicine Proposal - 1999  
Director, Yale Comprehensive Cancer Center Lymphoma Research Program  
Yale Medical Group Board of Governors  
Member of the New Clinical Program Development Fund - YNHH and Yale Medical School  
Steering Committee for Amistad Clinical Program Model Committee

PROFESSIONAL HONORS:

Member of the American Society for Clinical Investigation  
Member of the Association of American Physicians  
Irma T. Hirschl Career Investigator  
McKee Research Prize  
Citation Classic  
Dohi Award (Japanese Dermatologic Society)  
British Association of Dermatologists Annual Lecturer  
National Cancer Society Merit Award  
British Association of Dermatologists (Honorary Foreign Member)  
The Polish Association of Dermatology (honorary membership)  
The New England Cancer Society  
Dozor Visiting Scholar, Ben-Gurion University (Israel)  
Elected American Association for the Advancement of Science Fellow 1998  
M.H. Samitz Lecturer 2001, University of Pennsylvania  
Consult Professor of Shanghai Second Medical University 2002  
Annual Oration of the St. John's Hospital Dermatological Society, London, December 2003.

EDITORIAL BOARD SERVICE:

Journal of Investigative Dermatology  
Journal of Cutaneous Pathology  
Journal of Dermatologic Surgery and Oncology  
Journal of The American Academy of Dermatology  
British Journal of Dermatology

## REVIEWER FOR NIH STUDY SECTION:

General Medicine A (1986-90)  
Multiple Ad Hoc Site Visits and Grants

## NATIONAL EXECUTIVE COMMITTEES

National Cancer Institute Liaison for AAD  
Association of Professors of Dermatology  
Dermatology Foundation Leaders Society  
Nominating Committee of the Association of Professors of Dermatology  
Dermatology Foundation Vice President  
Dermatology Foundation Past Secretary-Treasurer

## MEDICAL SOCIETIES:

American Academy of Dermatology  
American Federation of Clinical Research  
Dermatology Foundation Leader's Society  
Society for Investigative Dermatology  
American Dermatology Association  
American Society for Advancement of Science  
Harvey Society  
National Institute of Health - FAES  
New York Academy of Sciences  
New England Dermatologic Association  
New Haven Medical Association  
Interurban Clinical Club

## VISITING PROFESSORSHIPS:

Dohi Lecturer (Japanese Dermatologic Society); Hammamatsu University (Japan); Keio University (Japan), British Association of Dermatologists, St. John's University (England), Japanese Dermatological Society, Kitasato Univ. (Japan), Univ. of Seoul (South Korea), Harvard (2), London Univ., Univ. of Kiel (W. Germany), Hosp. St. Louis (Paris), NYU (5), Cornell (2), Downstate, Einstein (5), Western Reserve, UCLA, Univ. of Calif (San Diego), Univ. of Michigan (2), Dartmouth (New Hampshire), Univ. of Pa (2), Emory (2), Univ. of Texas (Dallas), Univ. of Cincinnati, Brown, Tufts, Mt. Sinai, Cleveland Clinic, Mayo Clinic, Univ. of Bogota (Colombia), Univ. of Minnesota, Medical College S. Carolina, NIH (4), Univ. of Puerto Rico (2), Brooke Army Hospital, University of Vancouver, Medical College of Wisconsin, Karolinska Institute, Stockholm; University Dell Aquila (Rome); Marcus T. Block, M.D. University of Medicine & Dentistry (New Jersey); University of Miami; Northwestern; Dozor Visiting Scientist Ben Gurion University (Israel); University of Padua (Italy); University of Trujillo (Peru); Vanderbilt, Columbia, Boston University, Henry Ford Hospital, National Institutes of Health (4); IV Prague Dermatological Meeting (Prague); Fifth Asian Dermatologic Congress (Beijing, China); Annual Eastern Regional Meeting of the Japanese Dermatological Association (Hammamatsu, Japan); Wally Lobitz Lecturer, *Immunotherapeutic Jiu Jitsu: Using the Strength of the Immunologic System to Control Its Own Aberrations* 2) *Methods for Deciphering the Immuno-Enhancing Effects of Psoralens* 3) *The Cutaneous T Cell Lymphoma Algorithm: Decoding Inflammatory Diseases of the Skin*, Oregon Dermatology Society (Portland, Oregon); I International Dermatological Meeting Cuenca, Ecuador, February 1999; University of Puerto Rico, 1) *The Clinically Relevant Immunobiology of Cutaneous T Cell Lymphoma* 2) *Vaccination against Tumor Antigens of Cutaneous T Cell Lymphoma*, San Juan, Puerto Rico February 2000; Henry Ford Hospital, Detroit, 1) *The Clinically Relevant Immunobiology of Cutaneous T Cell Lymphoma* 2)

*Vaccination against Tumor Antigens of Cutaneous T-cell Lymphoma*, April 2000; Mt. Sinai School of Medicine, New York, *Vaccination Therapy for Cutaneous T-Cell Lymphoma and Autoreactive Skin Disease*, December 2000; Congress of the European Society for Haemapheresis (Malmo, Sweden); State University of New York, Brooklyn, *Immunologic Jiu-Jitsu: Using the Strength of the Immune System to Correct Its Own Aberrations*, May 2001; State of the Art on Cutaneous Lymphoma, Cambridge, MA September 28, 2001 *Use of Apoptotic Malignant T-cells as Immunogens*; Invited H.M. Samitz Lecturer in Cutaneous Medicine, *Immunologic Jiu-Jitsu, Using the Strength of the Immune System to Correct Its Own Aberrations*, Philadelphia, October, 2001; Annual Meeting of the Chilean Society of Dermatology, *Dermatology Practice in the USA-non-university private practice vs. university private practice*, Clinica Alemana, Pucon, Chile, November 2001; British Photodermatology Group/ United Kingdom Skin Lymphoma Group Workshop on Photopheresis, 1) *Mechanism of Action of Photopheresis* 2) *Future Directions for Photopheresis*, Belfast, Ireland December, 2001; International Symposium Biology & Immunology of Cutaneous Lymphoma, 1) *Tumor associated Antigens in Cutaneous Lymphoma* 2) *Vaccination therapies*, Berlin January, 2002; Protein Transduction Strategies: Current Principles and Application to Cutaneous T Cell Lymphoma, National Cancer Institute, *Overview of Cutaneous T Cell Lymphoma*, Bethesda, Maryland, February, 2002; Valley of the Sun Conference on Clinical Dermatology, Scottsdale, Arizona, April 2002; Invited Speaker - Dr. Lloyd King Symposium, *The Evolution of CTCL and Extracorporeal Photochemotherapy*, Vanderbilt University, Nashville, Tennessee June 2002; Invited speaker SID, *Deciphering the Mechanism by which Ultraviolet Therapy Increases Malignant Cell Immunogenicity*, Los Angeles, California May 2002; 20<sup>th</sup> World Congress, Paris, France, July 2002 *Future Directons for Photopheresis*; State of the Art on Cutaneous Lymphomas, Boston, Massachusetts September 2002; Invited Lecturer H&H Dermatology Seminar, Miami, Florida October 2002; Young Leaders in Dermatology *Cutaneous T Cell Lymphoma improved evaluation and treatment: Learning to speak the language of the malignant cells*, Tucson, Arizona, October 2002; Invited Lecturer Shanghai Second Medical University, *The Clinically Relevant Immunobiology of Cutaneous T Cell Lymphoma* 2) *Vaccination against Pathogenic T Cells, both Malignant and Autoimmune, with Transimmunization/ Photopheresis*, Shanghai, China January 2003; NCI Protein Workshop, International Symposium of Cutaneous Biology and Selective Immunotherapy against CTCL, Washington DC, February, 2003; Invited Lecturer Cell Therapy: the State of Art and New Perspectives Workshop 1) *Modulation of Immune System by Extracorporeal Photochemotherapy* 2) *Transimmunization: Correcting the Flaws of ECP*, Pavia, Italy, May 2003; Invited lecturer Annual Meeting of the YNH Auxiliary, *Outsmarting Cancer Cells by Learning the Language They Speak*, October, 2003; Invited Lecturer Lymphoma Research Foundation *Cutaneous T Cell Lymphoma and Mycosis Fungoides: 2003 Educational Forum on Lymphoma*, Washington DC, October 25, 2003; Invited Lecturer *International Society for Apheresis*, Nashville, Tennessee, October 30, 2003: 1) *Learning to Outmaneuver Cutaneous T Cell Lymphoma by Deciphering the Language that the Malignant Cells Speak*, 2) *Transimmunization: patient specific anti-tumor immunotherapy*, October 2003; Invited Hermann Pinkus Lecturer to Michigan State Dermatology Society, Wayne State University, November 12, 2003, 1) *Learning to Outsmart Cutaneous T Cell Lymphoma by understanding the language that the malignant cells speak*; 2) *Patient Specific Vaccination Against Malignant Cells* ; St. John's Hospital Dermatological Society, London, December 4, 2003 *Langerhans Cells Apppearu to Stimulate CTCL Cell Growth*; Invited Jack & Marjorie Gunn Lectureship, University of Columbia, Missouri, May 2004. *Learning to Outsmart the Malignant Cells of Cutaneous T Cell Lymphoma*; 5<sup>th</sup> European Congress of Oto-Rhino-Laryngology Head & Neck Surgery, Rhodes, Greece 1) *Keynote lecture: Learning to Vaccinate Patients against their own solid tumors* 2) *Keynote lecture: New Methods of Immunotherapy for Solid Tumors*, September 11-17, 2004; International Symposium on Biology & Immunology of Cutaneous Lymphoma, Berlin, Germany February 3, 2005, *Cutaneous T Cell Lymphoma: proliferation of T-regulatory Cells*; Grand Rounds Norris Cotton Cancer Center, Dartmouth Hitchcock, September 15, 2005; AABB Annual Meeting, Seattle, WA "*Immunotherapy through Extracorporeal Photochemotherapy*" October 15, 2005; Valley of the Sun, Phoenix, Arizona "*Cutaneous T Cell Lymphoma*", April 4, 2006; 21<sup>st</sup> World Congress, Buenos Aires, Argentina, "*Vaccination for Cutaneous T Cell Lymphoma*," October 2, 2007; Arthur C. Curtis Visiting Professor, University of Michigan "*Immunoloic Jiu Jitsu – Strides Towards Using Malignant Cells to Immunize Against*

Themselves,” “Outmaneuvering CTCL Cells by Intercepting and Decoding Their Own Cellular Conversations,” March 12-13, 2008; Grand Rounds Montefiore Hospital “*Striving to Immunize against Cancer*,” April 10, 2008.

## PUBLICATIONS:

### Original Research Reports:

1. Edelson RL, Smith RW, Frank MM and Green I. Identification of subpopulations of mononuclear cells in cutaneous infiltrates: differentiation between B cells, T cells, and histiocytes. *J Invest Dermatol* 61:82-89, 1973.
2. Edelson RL, Kirkpatrick G, Shevach E, Schein P, Smith R, Green I and Lutzner MA. Preferential cutaneous infiltration by thymus-derived lymphocytes. *Ann Intern Med* 80: 685-692, 1974.
3. Shevach EM, Edelson RL, Frank MM, Lutzner MA and Green I. A human leukemia cell with both B and T cell surface receptors. *Proc Natl Acad Sci* 71: 863-866, 1974.
4. Edelson RL, Facktor M, Andrews A, Lutzner MA and Schein P. Successful management of the Sezary syndrome: mobilization and removal of extravascular neoplastic T cells by leukapheresis. *New Engl J Med* 291: 293-294, 1974.
5. Edelson RL, Lutzner MA, Kirkpatrick CH, Shevach EM and Green I. Morphologic and functional properties of the atypical T lymphocytes of the Sezary syndrome. *Mayo Clin Proc* 49: 558-566, 1974.
6. Yoshida T, Edelson R, Cohen S and Green I. Migration inhibitory in serum and cell supernatants in patients with Sezary syndrome. *J Immunol* 114: 914-918, 1975.
7. Gerna-Torsellini M, Edelson RL, Frank MM and Kaplan A. Identification of subpopulations of mononuclear cells in cutaneous infiltrates. II. Urticaria. *Bollettino Sieroterapica Milanese* 54: 24-30, 1975.
8. Edelson RL, Hearing VJ, Dellon AL, Frank MM, Edelson EK and Green I. Differentiation between B cells and histiocytes in melanocytic lesions: Primary and metastatic melanoma and halo and giant pigmented nevi. *Clin Immunol and Immunopath* 4: 557-568, 1975.
9. Broder S, Edelson R, Lutzner M, Nelson D, MacDermott R, Durm M, Goldman C, Meade B and Waldman T. The Sezary Syndrome: A malignant proliferation of helper T cells. *J Clin Invest* 58: 1297-1306, 1976.
10. Dellon L, Edelson R and Chretien P. Defining the malignant potential of giant pigmented nevi. *Plastic Reconstr Surg* 57: 611-618, 1976.
11. Weng-Peng J, Lutzner M and Edelson R. Cytogenetic studies and clinical implications in patients with Sezary syndrome. *Cancer* 38: 861-867, 1976.
12. Gerna Tosellini M and Edelson RL. Identificajione delle Cellule Sinformonocitarie degli infiltrati mediante marcatura con eritrociti di montone dei recettori specifici di membrana. *Bollettino Della Societa Intaliana di Biologia Sperimentale* 51: 917-921, 1976.
13. Edelson RL. Efficacy of leukapheresis procedures in the management of cutaneous T cell

lymphoma-leukemic phase. *Proceed. of the 4th Advanced Blood Components Seminar* 1-7, 1977.

14. Edelson RL, Brown J, Grossman M and Hardy M. Anti-thymocyte globulin in treatment of T cell lymphoma. *Lancet* II: 1-7, 1977.
15. Edelson RL, Finkelman F, Steinberg A, Ahmed A, Broder S, Strong D and Green I. Reactivity of lupus erythematosus antibodies with leukemic helper T cells. *J Invest Dermatol* 70: 42-44, 1978.
16. Edelson RL, Berger C, Raafat J and Warburton D. Karyotype studies of cutaneous T cell lymphoma: evidence for clonal origin. *J Invest Derm* 73: 548-550, 1979.
17. Schackney S, Edelson R and Bunn P. The kinetics of Sezary cell production. *Cancer Treat Rep* 63: 659-662, 1979.
18. Berger C and Edelson R. Comparison of lymphocyte function after isolation by ficoll-hypaque flotation or elutriation. *J Invest Derm* 73: 231-235, 1979.
19. Berger C, Warburton D, Raafat J, LoGerfo P and Edelson R. Cutaneous T cell lymphoma: Neoplasm of T cell with helper activity. *Blood* 53: 642-650, 1979.
20. Edelson RL, Raafat J, Berger CL, Grossman M, Troyer C and Hardy M. Antithymocyte Globulin in the Management of Cutaneous T Cell Lymphoma. *Cancer Treat Rep* 63: 675-680, 1979.
21. Rubinfeld MR, Edelson RL, Lofstrom L and Warburton D. Neoplastic human T cells capable of responding to multiple alloantigens. *Blood* 55: 470-473, 1980.
22. Kung PC, Berger CL, Goldstein G, LoGerfo P and Edelson RL. Cutaneous T cell lymphoma - characterization by monoclonal antibodies. *Blood* 57: 261-266, 1981.
23. Fithian E, Kung P, Goldstein G, Rubinfeld M, Fenoglio C and Edelson R. Reactivity of Langerhans cells with hybridoma antibody. *Proc Natl Acad Sci USA* 78: 2541-2544, 1981.
24. Bunn P, Edelson R, Ford S and Shackney S. Patterns of cell proliferation and cell migration in the Sezary syndrome. *Blood* 57: 452-463, 1981.
25. Rubinfeld MR, Silverstone AE, Knowles DM, Halper JP, DeSostoa A, Fenoglio CM and Edelson RL. Induction of lymphocyte differentiation by epidermal cultures. *J Invest Derm* 77: 221-224, 1981.
26. DiPietro WP, Berger C, Harber LC and Edelson RL. Normal numbers of phenotypic helper, suppressor, and total T cell populations in psoriasis vulgaris: Quantitation by monoclonal antibodies. *J Amer Acad Derm* 5: (3): 304-307, 1981.
27. Berger CL, Kung P, Goldstein G, DiPietro W, Takezaki S, Chu A, Fithian E and Edelson RL. Use of orthoclone monoclonal antibodies in the study of selected dermatologic conditions. *Int J Immunopharmac* 3: 275-282, 1981.
28. Fenoglio C, Oster MW, LoGerfo P, Reynolds T, Edelson RL, Patterson JAK, Madeiros E and McDougall JK. Kaposi's sarcoma following chemotherapy for testicular cancer in a homosexual man: Demonstration of cytomegalovirus RNA in sarcoma cells. *Human Pathology* 13: 955-959, 1982.

29. Berger CL, Morrison SL, Chu A, Patterson J, Estabrook A, Takezaki S, Sharon J, Warburton, Irigoyen O, and Edelson RL. Diagnosis of cutaneous T cell lymphoma by use of monoclonal antibodies reactive with tumor-associated antigen. *J Clin Invest* 70: 1205-1210, 1982.
30. Takezaki S, Morrison SL, Berger CL, Kung PC, Chu AC and Edelson RL. Biochemical characterization of a differentiation antigen shared by human epidermal Langerhans cells and cortical thymocytes. *J Clin Immunol* Vol. 2 (3): 128S-134S, 1982.
31. Chu A, Eisinger M, Lee S, Takezaki S, Kung PC and Edelson RL. Immunoelectron microscopic identification of Langerhans cells using a new antigenic marker. *J Invest Derm* 78: 177-180, 1982.
32. Chu AC, Goldstein G, Patterson JAK, Berger CL, Takezaki S and Edelson RL. Thymopoietin-like substance in human skin. *Lancet* Vol. II, No. 8301, pp. 766, 1982.
33. Chu A, Berger CL, Kung PC and Edelson RL. In situ identification of Langerhans cells in the dermal infiltrate of cutaneous T cell lymphoma. *J Amer Acad Dermatol* 6: 350-354, 1982.
34. Chu A, Patterson JAK, Berger CL and Edelson RL. T cell subpopulations of cutaneous T cell lymphoma (CTCL). *J Invest Derm* 78: 334, 1982.
35. Chu AC, Goldstein G, Berger CL, Takezaki S, Patterson JAK and Edelson RL. Thymopoietin-like substance in human skin. *J Invest Dermatol* 81: 194-197, 1983.
36. Estabrook A, Berger CL, LoGerfo P, Hardy M and Edelson RL. Antigenic modulation of T lymphocytes by monoclonal antibodies. *Transplant Proc* 15: 651, 1983.
37. Estabrook A, Mittler R, LoGerfo P, Edelson RL and Berger CL. Antigenic modulation of pan-T cell and T-cell subset specific markers. *Diag Immunol* 1: 199-204, 1983.
38. Patterson JAK, Griffiths-Chu S, Berger CL, Edelson RL and Chu AC. Recognition of immature T-cell phenotypes in neonatal blood using monoclonal antibodies. *Diag Immunol* 1: 205-210, 1983.
39. Chu A, Patterson J, Berger C, Vonderheid E and Edelson RL. In situ study of T-cell subpopulations in cutaneous T cell lymphoma. *Cancer* 54: 2414-2422, 1984.
40. Griffiths-Chu S, Patterson JAK, Berger CL, Edelson RL and Chu AC. Characterization of immature T cell populations in neonatal blood. *Blood* 64: 296-300, 1984.
41. Gasparro FP, Berger CL and Edelson RL. Effect of monochromatic UV-A light and 8-methoxypsoralen on human lymphocyte response to mitogen. *Photodermatology* 1: 10-17, 1984.
42. Patterson JAK, Haynes BF, Eisinger M, Berger CL and Edelson RL. Monoclonal antibody reactive with basal layer keratinocytes: studies in the normal and a hyperproliferative states. *J Invest Derm* 83 (3): 210-213, 1984.
43. Gasparro FP, Saffran WA, Cantor CR and Edelson RL. Wavelength dependence for AMT crosslinking of pBR322 DNA. *Photochem and Photobiol* 40: 215-219, 1984.
44. Murphy RF, Bisaccia E, Cantor RC, Berger CL and Edelson RL. Internalization and acidification of insulin by activated human lymphocytes. *J Cell Physiol* 121 (2): 351-356, 1984.

45. Berger CL, Cantor C, Welsh J, Dervan P, Begley T, Grant S, Gasparro FP and Edelson RL. Comparison of synthetic psoralen derivatives and 8MOP in the inhibition of lymphocyte proliferation. The medical and biological effects of light. *Ann NY Acad Sci* 454: 80-90, 1985.
46. Edelson RL and Fink J. Immunologic function of skin. *Scientific American* 252: 46-53, 1985.
47. Santella RP, Dharmaraja N, Gasparro FP and Edelson RL. Monoclonal antibodies that recognize 8-MOP modified DNA. *Nucleic Acid Res* 13: 2533-2544, 1985.
48. Kaudewitz P, Kind P, Burg G, Rieber P, Berger C, Edelson R and Braun-Falco O. Longitudinal study of surface antigen pattern in cutaneous T-cell lymphomas. *Proc of the European Congress on Immunohistology*. Cambridge University Press, 123-124, 1985.
49. Yemul SS, Berger C, Estabrook A, Edelson R and Bayley H. The delivery of phototoxic drugs to selected cells. *NY Acad Sci* 446: 403-414, 1985.
50. Gasparro FP, Bagel J and Edelson RL. HPLC analysis of 8-MOP photoadducts in calf thymus DNA, poly (dAdT.dAdT), poly(dA.dT) and poly(dT). *Photochem Photobiol* 42: 98-101, 1985.
51. Gasparro FP, Chan G and Edelson RL. Phototherapy and photopharmacology. *Yale J Biol and Med* 58: 519-534, 1985.
52. Berger CL, Friedman-Kien AE, DiFranco M, Rehle T, Ostreicher R, Knobler R, Donofrio S, Laubenstein L and Edelson RL. Common membrane antigen on lymphocytes from cutaneous T cell lymphoma and acquired immune deficiency syndrome patients recognized by monoclonal antibody BE2. *J Invest Derm* 87: 280-283, 1986.
53. Gasparro FP, Yemul SS, Knobler RM and Edelson RL. Receptor mediated photocytotoxicity. Synthesis of a photoactivatable psoralen derivative conjugated to insulin. *Biochem Biophys Res Comm.* 141: 502-509, 1986.
54. Gasparro FP, Song J, Knobler RM and Edelson RL. Quantitation of psoralen photoadducts in DNA isolated from lymphocytes treated with 8-methoxypsoralen and ultraviolet A light (Extracorporeal Photopheresis) in *Current Problems in Dermatology* 15: 67-84, 1986.
55. Edelson RL, Berger CL, Gasparro F, Jegasothy B, Heald PW, Wintroub B, Vonderheid E, Knobler R, Wolffe K, Plewig G, McKiernan G, Christensen I, Oster M, Honigsmann H, Wilford H, Kokoschka E, Rehle T, Perez M, Stingl G and Laroche L. Treatment of Cutaneous T Cell Lymphoma by Extracorporeal Photochemotherapy: Preliminary Results. *New Eng J Med* 316: 297-303, 1987.
56. Yemul S, Berger C, Estabrook A, Suarez S, Edelson R and Bayley H. Selective killing of T lymphocytes by phototoxic liposomes. *Proc Natl Acad Sci* 84: 246-250, 1987.
57. Bayley H, Gasparro FP and Edelson RL. Photoactivatable drugs. *Trends in Pharmacological Sciences* 8: 138-143, 1987.
58. Heald PW and Edelson RL. New therapies for cutaneous T cell lymphoma. *Arch Derm* 123: 189-191, 1987.
59. Knobler RM, Rehle T, Grossman M, Saxinger CW, Berger CL, Oster M, McKiernan G and Edelson RL. Clinical evolution of cutaneous T cell lymphoma in a patient with antibodies to human T-lymphotrophic virus Type I. *J Amer Acad Derm* 17: 903-909, 1987.

60. Warburton D, Shapiro P, Berger C and Edelson RL. Clonal chromosomal abnormalities in cutaneous T cell lymphoma. *Cancer Genet Cytogenet* 28: 267-276, 1987.
61. Chu T, Berger C, Morris J and Edelson RL. Induction of an immature T cell phenotype in malignant helper T cells by co-cultivation with epidermal cell cultures. *J Invest Derm* 89: 358-361, 1987.
62. Gasparro FP, Knobler RM, Weingold DH, Yemul SS and Edelson RL. Photoactivation of a psoralen derivative conjugated to insulin. *Ann NY Acad Science* Vol. 507, p. 339-340, 1987.
63. Longley BJ, Braverman IM, Edelson RL. The skin as an immunologic organ. *Ann NY Acad Sci*, 548: 225-232, 1988.
64. Edelson RL. Light-activated Drugs. *Scientific American* 259: 68-75, 1988.
65. Berger CL, Eisenberg A, Soper L, Chow J, Simone J, Gapas Y, Cacciapaglia B, Bennett L, Edelson RL, Warburton D and Benn P. Dual genotype in cutaneous T cell lymphoma: Immunoglobulin gene rearrangement in clonal T cell malignancy. *J Invest Derm* 90: 73-77, 1988.
66. Saffran WA, Welsh J, Gasparro FP, Knobler RM, Cantor CR and Edelson RL. Synthesis and characterization of a biotinylated psoralen. *Nucleic Acids Res* 16: 7221-7321, 1988.
67. Gasparro FP, Battista J, Song J and Edelson RL. Rapid and sensitive analysis of 8-methoxypsoralen in plasma. *J Invest Dermatol* 90:234-236, 1988.
68. Gasparro FP, Knobler RM, Saffran WA and Edelson RL. Photochemistry of Gilvocarcin: An Antitumor Antibiotic. *Chem Biol Interactions* 67: 267-274, 1988.
69. Longley J, Kraus J, Alonso M, Edelson RL. Molecular cloning of CD1a (T6), A Human epidermal Dendritic Cell Marker Related to Class I MHC Molecules. *J Invest Derm*, 92: 628-631, 1989.
70. Perez MI, Edelson RL, Laroche LL and Berger CL. Inhibition of anti-skin allograft immunity by infusions with syngeneic photoinactivated effector lymphocytes. *J Invest Derm* 92: 669-676, 1989.
71. Heald P, Perez M, McKiernan G, Christensen I, Edelson R. Extracorporeal photochemotherapy: Indications, methodology, safety aspects, side effects and long-term results. *Photodermatology* 6:171, 1989.
72. Edelson RL. Photopheresis: A new therapeutic concept.. *The Yale J Bio and Med*, 62, 6, Nov-Dec, pp. 565-578, 1989.
73. Perez MI, Edelson RL, John L, Laroche L and Berger CL. Inhibition of Antiskin allograft immunity induced by infusions with Photoactivated Effector T lymphocytes (PET cells). *The Yale J Biol and Med*, 62: 595-609, 1989.
74. Edelson R. Photopheresis. *Jour Clin Apheresis*. 5:77-79, 1990.
75. Gasparro FP, Dall'Amico R, O'Malley M, Heald PW, Edelson RL. Cell Membrane DNA: A New Target for Psoralen Photoadduct Formation. *Photochem Photobiol* 52: 315-321, 1990.
76. Berger CL, Perez M, Laroche L, Edelson R. Inhibition of autoimmune disease in a murine model of systemic lupus erythematosus induced by exposure to syngeneic photoinactivated lymphocytes. *J Invest Derm* 94, 52-57, 1990.

77. Heald PW, Berger CL, Yamamura T, McNamara J, Edelson RL. BE-2 Antigen: Appearance during T cell activation and increase with stimulation and growth of T cells. *J Invest Derm* 94: 452-455, 1990.
78. Heald PW, Perez MI, McKiernan G, Christensen I, Edelson RL. Extracorporeal Photochemotherapy for CTCL. *Apheresis*, pg. 443-447, 1990.
79. Rook A, Jegasothy B, Heald P, Nahass G, Ditre C, Witmer W, Lazarus G, Edelson RL: Extracorporeal photochemotherapy for drug resistant pemphigus. *Ann Int Med* Feb 15, 112:303-305, 1990.
80. Heald P, Perez M, Christensen I, McKiernan G, Edelson R: Treatment of cutaneous T-cell lymphoma: The Yale-New Haven Hospital experience. *Yale J Biol Med* 62:629-638, 1990.
81. Edelson RL. Photopheresis - Present and Future Aspects. News & Views Section. *J Photochem Photobiol.* 10: 165-174, 1991.
82. Tokura Y, Edelson RL, Gasparro FP. Formation and Removal of 8-MOP-DNA photoadducts in keratinocytes: Effects of calcium concentration and retinoids. *J Invest Derm* 96: 942-949, 1991.
83. Bevilacqua PM, Edelson RL, Gasparro FP. HPLC Analysis of 8-Methoxypsoralen Monoadducts and Crosslinks in Lymphocytes and Keratinocytes. *J Invest Derm* 97: 151-155, 1991.
84. Edelson RL. Photopheresis: a Clinically Relevant Immunobiologic Response Modifier. *Ann Am Acad Sci* 636: 154-164, 1991.
85. Malawista SE, Trock D, and Edelson RL. Photopheresis for Rheumatoid Arthritis. *Ann Am Acad Sci* 636: 217-226, 1991.
86. Tokura Y, Yagi J, Edelson RL, Gasparro FP. Inhibitory effect of 8-MOP plus UVA on IL-1 production by murine epidermal keratinocytes. *Photochem Photobiol* 53: 517-523, 1991.
87. Gasparro FP, Edelson RL, O'Malley ME, Ugent SJ, Wong HH. Photoactivatable Antisense DNA: Suppression of Ampicillin Resistance in Normally Resistant *Escherichia coli*. *Antisense Res & Dev*, 1: 117-140, 1991.
88. Heald P, Edelson R: The immunobiology of cutaneous T-cell lymphoma. *J Nat Cancer Inst* 83: 400, 1991.
89. Malawista SE, Trock DH, Edelson RL. A Pilot Study. Treatment of Rheumatoid Arthritis by extracorporeal photochemotherapy. *Arthritis and Rheumatism*, 34:6, 646-654, 1991.
90. Perez MI, Berger CL, Yamane Y, John L, Laroche L, Edelson RL. Inhibition of Antiskin Allograft Immunity Induced by infusions with photoinactivated effector T lymphocytes (PET cells). The Congenic Model. *Transplantation* 51: 1283-1289, 1991
91. Yamane Y, Perez MI, Edelson R, Agostino N, Pernis B. Endocytosis of the TCR, CD3 Complex and Class-I major histocompatibility antigens in a human T cell line. *Cellular Immunology* 136: 496-503, 1991.
92. Perez MI, Lobo F, Yamane Y, John L, Berger CL, Edelson RL, Inhibition of antiskin allograft immunity induced by infusions with photoinactivated effector T cell lymphocytes (PET cells). Is in

vivo cell transferable? *Annals NY Acad Sci* 636:95-112, 1991.

93. Yamane Y, Perez MI, John L, Edelson R. Effect of prednisolone and cyclophosphamide on inhibition of the response to alloantigen induced by treatment with photoinactivated effectors T cells (PET cells). *Annals NY Acad Sci* 636:406-408, 1991.
94. Laroche L, Edelson RL, Perez MI, Berger C. Antigen-specific tolerance induced by autoimmunization with photoinactivated syngeneic effector cells. *Annals NY Acad Sci* 636:113-123, 1991.
95. Berger CL, Edelson RL, Edwards N, Sanchez J, Coppey L, He X, Marboe C, Rose E. Autoregulation of the Immune Response in Autoimmune Disease and Cardiac Transplantation by Photoinactivated Autologous Lymphocytes. *Annals NY Acad Sci* 636: 266-278, 1991.
96. Ding TG, Qiu BS, Kolenik SA, Yan SL, Longley BJ, Edelson RL. In situ transcription and detection of CD1a mRNA in human skin. *J Chinese Medicine* 71(1): 6-8, 1991.
97. Ding TG, Qiu BS, Kolenik SA, Yan SL, Wang XM, Longley BJ, Edelson RL. Effect of interleukin-1, tumor necrosis factor and granulocyte macrophage-colony stimulating factor on CD1a expression by human epidermal Langerhans cells. *J Chinese Dermatology* 24(4): 219-221, 1991.
98. Ding TG, Yan SL, Kolenik SA, Wang XM, Qiu BS, Longley BJ, Edelson RL. Expression of transfected CD1a: Development of an immunophenotypic model of human epidermal Langerhans cells in vitro. *J Chinese Dermatology* 24(6): 401-404, 1991.
99. Tokura Y, Heald PW, Yan SL, Edelson RL. Stimulation of Cutaneous T-cell Lymphoma Cells with Superantigenic Staphylococcal Toxins. *J Invest Dermatol* 98: 33-37, 1992
100. Rook AH, Freundlich B, Jegasothy BV, Perez MI, Barr WG, Jimenez SA, Rietschel RL, Wintroub B, Kahaleh MB, Varga J, Heald PW, Steen V, Massa MC, Murphy GF, Perniciaro C, Istfan M, Ballas SK, Edelson RL. Treatment of Systemic Sclerosis with Extracorporeal Photochemotherapy: Results of a Multicenter Trial. *Arch Derm* 128: 337-346, 1992.
101. Heald P, Buckley P, Gilliam A, Perez M, Knobler R, Kacinski B, Edelson R. Correlations of Unique Clinical Immunotypic, and Histologic findings in Cutaneous Gamma/Delta T-Cell. *J Amer Acad Derm* 26: 865-870, 1992.
102. Perez, MI, Yamane Y, John L, Gasparro FP, Edelson RL. DNA associated with the cell membrane is involved in the inhibition of the skin rejection response induced by infusions of photodamaged alloreactive cells that mediate rejection of skin allograft. *Photochem Photobiol* 55: 839-849, 1992.
103. Tokura Y, Edelson RL, Gasparro FP. Retinoid augmentation of bioactive interleukin-1 production by murine keratinocytes. *British Jnl Derm* 126: 485-495, 1992.
104. Yamane Y, Lobo FM, John LA, Edelson RL, Perez MI. Suppression of anti-skin-allograft response by photodamaged effector cells-the modulating effects of prednisolone and cyclophosphamide. *Transplantation* 54: 119-124 1992.
105. Heald P, Rook A, Perez M, Wintroub B, Knobler R, Jegasothy B, Gasparro F, Berger C, Edelson R. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. *J*

Am Acad Derm 27 (3):427-433, 1992.

106. Kono DW, Baccala R, Balderas RS, Kovac SJ, Heald PW, Edelson RL, Theofilopoulos AN. Application of a multiprobe RNase protection assay and junctional sequences to define V gene diversity in Sezary syndrome. *Am J Pathol* 140:823-830, 1992.
107. Perez M, Lobo F, John L, Edelson RL. Induction of a cell-transferable suppression of alloreactivity by photodamaged lymphocytes. *Transplantation* 54:896-903, 1992.
108. Ding TG, Qiu BS, Kolenik SA, Yan SL, Wang XM, Longley BJ, Edelson RL. Effect of granulocyte macrophage colony-stimulating factor on mixed lymphocyte-epidermal cell culture. *J Chinese Dermatology* 25(2): 88-90, 1992.
109. Heald PW, Yan SL, Edelson RL, Tigelaar R, Picker LJ. Skin-Selective Lymphocyte Homing Mechanisms in the Pathogenesis of Leukemic Cutaneous T-Cell Lymphoma. *J Invest Dermatol* 101:222-26, 1993.
110. Frieden TR, Bia FJ, Heald PW, Eisen RN, Patterson TF, and Edelson RL. Cutaneous cryptococcoses in a patient with cutaneous T cell lymphoma receiving therapy with photopheresis and methotrexate. *Clin. Inf. Dis.* 17:776-778, 1993.
111. Tokura Y, Edelson RL, Gasparro FP. Modulation of 8-Methoxypsoralen-DNA Photoadduct Formation by Cell differentiation, mitogenic stimulation and phorbol ester exposure in murine T lymphocytes. *Photochem and Photobiol.* 58:6: 822-826, 1993.
112. Perez MI, Edelson RL. Regulation of Immunity by Ultraviolet Radiation and Photosensitized Reactions. *Chemical Immunol* 58: 314-330, 1994.
113. Tokura Y, Yagi J, O'Malley M, Lewis JM, Takigawa M, Edelson RL and Tigelaar RE. Superantigenic Staphylococcal Exotoxins Induce T-Cell Proliferation in the presence of Langerhans Cells or Class II-Bearing keratinocytes and stimulate keratinocytes to produce T-cell-activating cytokines. *J Invest Dermatol* 102: 31-38, 1994.
114. Edelson RL, Perez M, Heald P, Berger C. Extracorporeal Photochemotherapy. *Biologic Therapy of Cancer*, J.B. Lippincott Co., V. DeVita, S. Hellman, S. Rosenberg, Editors. 4(5):1-12, 1994.
115. Schmitt IM, Maxwell VM, Olack GA, Edelson RL, Chimenti S, Gasparro FP. The specific effects of 8-methoxypsoralen photoadducts on cell growth: HPLC analysis of monoadduct and crosslink formation in cells exposed to split-dose treatment. *J Photochem and Photobiol B: Biol.*, 22: 17-21, 1994.
116. Heald P, Yan SL, Latkowski J, Edelson R. Deficiency in normal and circulating T-cells in erythrodermic cutaneous T-cell lymphoma. *Arch Dermatol* 130:198-203, 1994.
117. Longley J, Tyrrell L, Lu, S-Z, Farrell J, Ding T, Yan S, Sallee D, Heald P, Berger C, Tigelaar R, Edelson R. Malignant and Normal T Cells Show Random Use of T-cell Receptor Chain Variable Regions in Patients with Cutaneous T-cell Lymphoma. *J Invest Dermatol* 105:62-64, 1995.
118. Wilson LD, Licata AL, Braverman IM, Edelson RL, Heald PW, Feldman AM, Kacinski BM. Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. *Int J Rad Oncol* 32:987-995, 1995.

119. Heald PW, Kim HY, Perez M, Edelson R, Berger CL. T-cell responses in Photoimmune therapy. *J Clin Apheresis*, 10:144-149, 1995.
120. Berger CL, Wang N, Christensen I, Longley J, Heald P, Edelson RL. The immune response to class I associated tumor-specific cutaneous T cell lymphoma antigens. *J Invest Dermatol* 107:392-397, 1996.
121. Wilson LD, Quiros PA, Kolenik SA, Heald PW, Braverman IM, Edelson RL & Kacinski BM. Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma. *J Amer Acad Derm* 35: 69-73, 1996.
122. Quiros PA, Jones GW, Kacinski BM, Braverman IM, Heald PW, Edelson RL, Wilson LD. Total Skin Electron Beam Therapy Followed by Adjuvant Psoralen / Ultraviolet-A Light in the Management of Patients with T1 and T2 Cutaneous T-Cell Lymphoma (Mycosis Fungoides). *Int J Radiation Oncology Biol Phy* 38: 1027-1035, 1997.
123. Imaeda S, Felli A, Schmitt I, Chimenti S, and Edelson RL. Induction of Functional Empty Class I Major Histocompatibility Complex Glycoproteins by Photoactivated 8-Methoxypsoralen. *J Invest Dermatol* 107:887-890, 1996.
124. Fargnoli MC, Edelson RL, Berger CL, Chimenti S, Couture C, Mustelin T, Halaban R. Diminished TCR signaling in cutaneous T cell lymphoma is associated with decreased activities of Zap70, Syk and membrane-associated Csk. *Leukemia* 11: 1338-1346, 1997.
125. Berger CL, Dong Z, Hanlon D, Bisaccia E and Edelson RL. A Lymphocyte Cell Surface heat shock protein homologous to the endoplasmic reticulum chaperone, immunoglobulin heavy chain binding protein BIP. *Int J Cancer*: 71: 1077-1085, 1997.
126. Hanlon D, Berger C, and Edelson RL. Photoactivated 8-Methoxypsoralen Treatment Causes a Peptide-Dependent Increase in Antigen Display by Transformed Lymphocytes. *Int J of Cancer*, 78: 70-75, 1998.
127. Berger CL, Longley BJ, Imaeda S, Christensen I, Heald P, Edelson RL. Tumor-Specific Peptides in Cutaneous T Cell Lymphoma: Association with Class I Major Histocompatibility Complex and Possible Derivation from the Clonotypic T Cell Receptor. *Int J of Cancer*, 76: 304-311, 1998.
128. Edelson RL. Cutaneous T-Cell Lymphoma: A Model for Selective Immunotherapy. *The Cancer Journal from Scientific American*. Volume 4 (2): 62-71, 1998.
129. Schechner JS, Edelson RL, McNiff JM, Heald PW, Pober JS. Expression of Integrin  $\alpha 4 \beta 7$  on epidermotropic cutaneous T cells in cutaneous T cell lymphoma and spongiotic dermatitis. *Lab Invest* 79: 601-607, 1999.
130. Heald PW and Edelson RL. Cutaneous T Cell Lymphoma. In: *Malignant Tumors of the Skin*. Chu AC and Edelson RL, eds. Edward Arnold Publishers, London, pp. 138-145, 1999.
131. Edelson RL and Berger C. Extracorporeal photochemotherapy. In: *Malignant Tumors of the Skin*. Chu AC and Edelson RL, eds. Edward Arnold Publishers Limited, London, England, pp. 396-408, 1999.

132. Edelson, Richard L. Pemphigus - Decoding the Cellular Language of Cutaneous Autoimmunity. Editorial *New Engl J Med*, 343: 60-61, 2000.
133. Girardi M, Edelson RL. Cutaneous T-Cell Lymphoma: Pathogenesis and Treatment. *Oncology* 14:7 1061-1069, 2000.
134. Jillilla AP, Murren JR, Hamid KK, Longley BJ, Edelson RL, Cooper DL. P-glycoprotein expression and multidrug resistance in cutaneous T-cell lymphoma. *Cancer Invest.* 18(7): 609-13, 2000.
135. Berger CL, Xu AL, Hanlon D, Lee C, Schechner J, Glusac E, Christensen I, Snyder E, Holloway V, Tigelaar R, and Edelson RL. Induction of Human Tumor-Loaded Dendritic Cells. *Int J Cancer* 91: 438-447, 2001.
136. Edelson RL. The Helping Hand of Dendritic Cells. *Annals of the NY Acad Sci.* Vol. 941: 1, 2001.
137. Meech SJ, Edelson R, Walsh P, Norris DA and Duke RC. Reversible Resistance to Apoptosis in Cutaneous T Cell Lymphoma. *Annals of the NY Acad Sci.*, Vol. 941: 46-58, 2001.
138. Berger CL, Longley J, Hanlon D, Girardi M and Edelson R. The Clonotypic T Cell Receptor is a Source of Tumor-associated Antigens in Cutaneous T Cell Lymphoma. *Annals of the NY Acad Sci.*, Vol. 941: 106-122, 2001.
139. Berger CL, Hanlon D, Kanada D, Dhodapkar M, Lombillo V, Wang N, Christensen I, Howe G, Crouch J, El-Fishawy P, Edelson R. The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells. *Blood*, Vol.99: 8-2929-2939, 2002.
140. Edelson RL. Editorial. Transimmunization: the science catches up to the clinical success. *Transfusion and Apheresis Science*, 26: 177-180, 2002.
141. Berger CL, Hanlon D, Kanada D, Girardi M, Edelson RL. Transimmunization, a novel approach for tumor immunotherapy. *Transfusion and Apheresis Science*, 26: 205-216, 2002.
142. Girardi M, Berger C, Hanlon D, Edelson RL. Efficient Tumor Antigen Loading of dendritic Antigen Presenting Cells by Transimmunization. *Technology in Cancer Research and Treatment.* 1:1: 65-69, 2002.
143. Berger CL, Edelson RL. Current Concepts of the Immunobiology and Immunotherapy of Cutaneous T Cell Lymphoma: Insights Gained through Cross-talk between the Clinic and the Bench. *Leukemia & Lymphoma.* 44(10): pp. 1697-1703, 2003.
144. Girardi, M, Knobler R, Edelson R. Selective immunotherapy through extracorporeal photochemotherapy: yesterday, today, and tomorrow. *Hematology/Oncology Clinics of North America*, 17/6, p. 1391-1401, 2003.
145. Fletcher CL, Orchard GE, Hubbard V, Whittaker SJ, Edelson RL, Russell-Jones R. CD30+ Cutaneous Lymphoma in Association with Atopic Eczema. *Arch Dermatol.* 140: 449-454, 2004.
146. Berger CL and Edelson R. The Life Cycle of Cutaneous T Cell Lymphoma Reveals Opportunities for Targeted Drug Therapy. In *Current Cancer Drug Targets.* 4:609-619, 2004.

147. Berger CL, Tigelaar R, Cohen J, Mariwalla K, Trinh J, Wang N, Edelson RL. Cutaneous T cell lymphoma, malignant proliferation of T-regulatory cells. *Blood*. 105:1640-1647, 2004.
148. Salskov-Iversen M, Berger CL, Edelson RL. Rapid construction of a dendritic cell vaccine through physical perturbation and apoptotic malignant T cell loading. *Jrnl. Immune Based Therapies and Vaccines*. 3:4, 2005.
149. Wong HK, Wilson AJ, Gibson HM, Hafner MS, Hedgcock C, Berger CL, Edelson RL, Lim HW. Increased Expression of CTLA-4 in PBMC and Malignant T-Cells from Patients with Mycosis Fungoides (CTCL). *J. Invest Dermatol* 126:212-219, 2006.
150. Nebozhyn M, Loboda A, Kari L, Rook AH, Vonderheid EC, Lessin S, Berger C, Edelson R, Nichols C, Yousef M, Gudipati L, Shang M, Showe MK, Showe LC. Quantitative PCR on 5 genes reliably identifies CTCL patients with 5 to 99% circulating tumor cells with 90% accuracy. *Blood* 107: 3189-3196, 2006
151. Girardi M, Berger CL, Wilson LD, Christensen IR, Thompson KR, Glusac EJ, Edelson RL. Transimmunization for cutaneous T cell lymphoma: a Phase I study. *Leuk Lymph* 47:1495-1503, 2006.
152. Berger CL, Vasquez JG, Shofner J, Mariwalla K, Edelson RL. Langerhans cells: Mediators of immunity and tolerance. *Int J Biochemistry & Cell Biol* 38:1632-1636, 2006.
153. Berger CL, Shofner J, Vasquez JG, Mariwalla K, Edelson RL. Cancer Immunotherapy. *Cancer Therapy* 4:81-98, 2006.
154. Kuo PH, McClennan BL, Carlson K, Wilson LD, Edelson RL, Heald PW, Girardi M. FDG-PET/CT in the Evaluation of Cutaneous T-Cell Lymphoma. *Mol Imaging Biol* 10.1007/s11307-007-1027-y. 2007.

#### Review Articles and Chapters

1. Smith RW, Blaese RM, Hatchcock KS, Buell DN, Edelson RL and Lutzner MA. T and B lymphocyte markers in lymphoid cell research and in human diseases in Lymphocyte Recognition and Effector Mechanisms: Proceedings of the Eighth Leukocyte Culture Conference. Academic Press (New York), pages 127-132, 1974.
2. Lutzner MA, Edelson RL and Schein P. Sezary syndrome (chapter) In: *Current Dermatologic Management*. C. V. Mosby pp. 286-287, 1975.
3. Green I, Jaffe E, Shevach E, Edelson R, Frank M and Berard C: Determination of the origin of malignant reticular cells by the use of surface markers. Monograph - International Academy of Pathology - The Reticuloendothelial System, pages 282-300, 1975.
4. Edelson RL. Membrane properties of the abnormal cells of cutaneous T cell lymphomas. In: *Annals Intern Med*; 83: 536-542, 1975.
5. Edelson RL. Cutaneous T cell lymphomas - perspective. *Annals Intern Med*; 83: 548-552, 1975.
6. Edelson R. Cutaneous T cell lymphomas: Clues of a skin-thymus interaction. *J Invest Derm*; 67: 419-424, 1976.

7. Edelson R. Membrane markers of lymphocytes in cutaneous lymphomas, melanomas and systemic lupus erythematosus. *Int J Derm*; 15: 557-586, 1976.
8. Schein P, McDonald J and Edelson R. Cutaneous T cell lymphomas. *Cancer* 38: 1859-1861, 1976.
9. Edelson RL. Recent advances in the cutaneous T cell lymphomas. *Cancer Bulletin* 64: 209-244, 1977.
10. Lutzner M and Edelson R. Cellular identities in lymphomas. In: *Dermatology in General Medicine*, editors Fitzpatrick et al, McGraw-Hill Publishers, 1979.
11. Edelson RL. Cutaneous T cell lymphoma. In: *Dermatology Update*, Elsevier Press, New York, edited by S. Moschella, pp. 195-207, 1979.
12. Edelson R. Cutaneous T cell lymphoma (mycosis fungoides, Sezary syndrome and other variants). *J Amer Acad Derm* 2: 89-106, 1980.
13. Edelson R. Round cells of the epidermis. *J Invest Derm* 75: 96-102, 1980.
14. Edelson RL. Cutaneous T-cell lymphoma. *J Dermatol Surg Oncol* 6: 358-368, 1980.
15. Edelson RL. Other experimental observations. *J Dermatol Surg Oncol* 6: 388-389, 1980.
16. Gupta S, Safai B, Edelson R, Parrott D and Good R. Locomotion of T-cells from patients with cutaneous T-cell lymphoma. (Sezary syndrome and mycosis fungoides). *Cell Immunol* 50: 195-201, 1980.
17. Edelson RL. The immunology of lymphoreticular malignancies of the skin. In *Progress in Cutaneous Diseases*, Fleischmajer R (ed)., Grune & Stratton Publishers, 1981).
18. Edelson RL. Cutaneous T cell lymphoma, leukemic phase. In *Clinical Dermatology*, Demis et al editors, Harper & Row Publishers, 1981.
19. Edelson RL, Chu A, Takezaki S and Berger CL. The interaction of T-lymphocytes with epidermis. *Prog In Dis of Skin*, Vol. I, 177-188, 1981.
20. Edelson RL, Berger CL and Armstrong RB. Lymphopheresis in the treatment of the leukemic phase of cutaneous T-cell lymphoma and pemphigus vulgaris. In Nemo GJ and Taswell H (eds): *Proc Workshop on Therapeutic Plasmapheresis and Cytapheresis*, NIH PUBL. No. 2-1665, pp. 55-71. Rochester: U.S. Dept. Health and Human Services, 1981.
21. Berger CL and Edelson RL. Monoclonal antibodies: Powerful new tools for the clinician. *Arch Dermatol*, Vol. 118: 627-629, 1982.
22. Patterson JAK and Edelson RL. Cutaneous T cell lymphoma. *Med Clin of N Amer*, Vol. 66 (4): 895-913, 1982.
23. Patterson JAK and Edelson RL. Interaction of T cells with the epidermis. *Brit J Derm* 107: 117-122, 1982.

24. Chu A, Berger CL, Lynfield Y, Essee I and Edelson RL. Pathogenesis of cutaneous T cell lymphoma. In M. Goos and E. Christophers (eds): *Lymphoproliferative Diseases of the Skin*, pp. 57-64, 1982.
25. Heald PW, Edelson RL. Leukemic phase of cutaneous T-cell lymphoma. In: *Clinical Dermatology*, Vol. 4., CD93, 20-12, 1982.
26. Chu A and Edelson RL. Introduction to tumors of the lymphoreticular system. In: *Clinical Dermatology*, Vol. 4. Harper and Row, Philadelphia, 1982.
27. Berger CL, Edelson RL, Gasparro FP and Harber LC. Skin-associated lymphoid tissues and photo-diseases, theoretical considerations, in Krueger J and Daynes R (eds): *Clinical Photoimmunology*, CRC Press, 1983.
28. Berger CL, Chu A, Fithian E, Patterson J and Edelson RL. Monoclonal antibodies used for tissue diagnosis in situ and in the circulation of patients with a variety of dermatologic conditions. *Amer J Dermatopath* 5: 85, 1983.
29. Berger CL and Edelson RL. Networks of Immunity: Functions of the immune system. In: *Cutaneous Toxicity*, V.A. Drill and P. Lazar (eds), Raven Press, 163-169, 1983.
30. Kung PC, Berger CL, Estabrook A and Edelson RL. Monoclonal antibodies for clinical investigation of human T lymphocytes. *Int J Dermatol* 22: 67, 1983.
31. Berger CL and Edelson RL. Peripheral blood of patients with cutaneous T-cell lymphoma: studies using monoclonal antibodies. *J Cutan Pathol* 10: 467-478, 1983.
32. Patterson JAK and Edelson RL. Cutaneous T cell lymphoma. In: *Your Patient and Cancer*, pp. 91-98,
33. Patterson JAK and Edelson RL. Interaction of T lymphocytes with the epidermis: immunopathological studies. *J Cut Path* 10: 540-549, 1983.
34. Edelson RL. Pathogenesis of T cell lymphoma of skin. *J Amer Acad Derm* 9 (6): 957-960, 1983.
35. Bisaccia E and Edelson RL. Cutaneous T cell lymphoma. In *Dermatologic Allergy and Immunology*. C.V. Mosby, 1984.
36. Edelson RL. Extracorporeal Photopheresis. *Photodermatology (Editorial)* Vol. 1 (5): 209-210, 1984.
37. Shapiro PE and Edelson RL. Effects of retinoids on the immune system. In *Retinoids: New Trends in Research and Therapy*. Retinoid Symposium, Geneva. J.H. Saurat (ed), Karger, pp. 225-235, 1985.
38. Toback AC and Edelson RL. Pathogenesis of cutaneous T cell lymphoma. In: *Dermatologic Clinics* Vol. 3 pp. 605-614, October, 1985.
39. Santella RM, Gasparro FP and Edelson RL. Quantification of methoxsalen-DNA adducts with specific antibodies. In: *Carcinogenicity of Alkylating Cytostatic Drugs*. Schmahl, D. and Kaldor, J.M. (eds.) Lyon IARC 78: 127-139, 1986.
40. Knobler RM and Edelson RL. Cutaneous T Cell Lymphoma. *Medical Clinics of North America* 70:

No. 1, 109-138, 1986.

41. Knobler RM and Edelson RL. Lymphoma Cutis: T-Cell Type. In *Lymphoproliferative Disorders of the Skin*, editors George F. Murphy and Martin C. Mihm, Jr. Chapter 7 pp. 176-204, 1986.
42. Edelson RL. Cutaneous T cell lymphoma. (1987 Dohi Memorial Lecture) *The Jnl of Dermatology* 14: 397-410, 1987.
43. Patterson JAK and Edelson RL. Cutaneous T cell lymphoma and other leukemic and lymphomatous infiltrates of the skin. In: *Dermatology in General Medicine*. 3rd Ed. Fitzpatrick TP, Eisen AZ, Wolff K, Freedberg IM and Austen KF. McGraw Hill 1086-1118, 1987.
44. Edelson RL. Photopheresis therapy of cutaneous T cell lymphoma. *Japanese Jnl of Dermatology* 97: No. 12, 1361-1390, 1987.
45. Kupper TS and Edelson RL. The role of cytokines in the pathophysiology of T cell mediated skin disease. *J Dermatology* 14: 517-523, 1987.
46. Patterson JAK and Edelson RL. Skin diseases caused by specific cell types. In *Immunological Diseases*, 4th Ed. Max Samter (ed), Little Brown & Co. 1988.
47. Teltscher J, Shrishailam Y, Estabrook A, Berger C, Edelson R and Bayley H. Phototoxic Liposomes for Selective Destruction of T Lymphocytes: Experiments under Physiological Conditions. In: *Liposomes as Drug Carriers: Trends and Progress*. G. Gregoriadis ed. Wiley and Sons Ltd. 783-792, 1988.
48. Heald PW and Edelson RL. Photopheresis for T cell mediated diseases. *Adv Derm* 3: 25-40, 1988.
49. Knobler RM, Honigsmann H and Edelson RL. Psoralen phototherapies in psoralen - DNA photobiology. CRC Press 1988.
50. Heald PW, Edelson RL. Photopheresis for cutaneous T-cell lymphoma. *Keio Med Journal*, 37: 155, 1988.
51. Heald PW, Edelson RL: Cutaneous T Cell Lymphoma. In *Decision Making in Oncology*, Schein P (ed). 1989.
52. Edelson RL. Update on Photopheresis. *Dermatology Foundation Progress in Dermatology* Vol. 23, No. 1, March 1989.
53. Heald PW, Edelson RL: Photopheresis. In *Photochemotherapy*. Abel L (ed). 1989.
54. Heald PW, Edelson RL: Cutaneous T Cell Lymphoma. In *Dermatology*. Moschella S, Hurley H (eds). 1989.
55. Heald PW, Perez MI, McKiernan G, Christensen I, Edelson RL. Extracorporeal photochemotherapy for cutaneous T-cell lymphoma. *Apheresis*, 1:443-447, 1990.
56. Edelson RL. Treatment of Cutaneous T Cell Lymphoma. *Curr Probl Derm*, Karger S., Pub. Basel, Switzerland. Vol. 19,: pp 226-237, 1990.
57. Gasparro F, Bevilacqua P, Goldminz D, Edelson R. Repair of 8-MOP Photoadducts in Human Lymphocytes. *DNA Damage and Repair in Human Tissues*. Plenum Press 137-148, 1990.

58. Heald PW and Edelson RL. Pathophysiology of Cutaneous T Cell Lymphomas. In Pathophysiology of Cutaneous Diseases. Soter N, Baden H (eds). 1990.
59. Heald PW, Edelson RL. Cutaneous T Cell Lymphoma. In Hematology: Basic principles and practice. Benz EJ, Cohen HF, Furie B, Hoffman R, Shattil S (eds). Churchill Livingstone Press, New York, NY. Chapter 78, pp. 1008-1020, 1991.
60. Heald PW, Edelson RL. Tumors of the lymphoreticular system. In Clinical Dermatology. Demis J (ed). 1991.
61. Heald PW, Edelson RL. Photopheresis. In Photochemotherapy. Abel L (ed). 1991.

62. Heald PW, Edelson RL: Photopheresis: Past, present and future. In: Recent Advances in Dermatology. Churchill Livingstone, Robert Champion and Richard Pye, Editors. 9: Ch 4: 49-62, 1991.
63. Heald PW, Perez M, Edelson R: Photopheresis of cutaneous T-cell lymphoma: Response rates and mechanism of action. Lymphomas of the Skin. Yamada M, Nakajima H (eds) 1991.
64. Edelson R, Heald P, Perez M, Rook A. Photopheresis Update. Dermatology Foundation Progress in Dermatology, Vol. 25 1991.
65. Heald PW, Edelson RL. Cutaneous T Cell Lymphoma. In Hematology, 2E: Basic principles and practice. Churchill Livingstone Press, New York, NY. Chapter 85, In Press, 1994.
66. Edelson R. Cutaneous T cell lymphoma: a malignancy of a distinct subset of "cutaneous T cells". Cutaneous Lymphoma - 1993, edited by Mizuho Yamada, Honorary Editor and Masahiro Takigawa, Editor. Mokko Press, Hammamatsu, Japan, 1994.
67. Edelson, R, Heald P, Perez M, Berger C. Extracorporeal Photochemotherapy. Biologic Therapy Updates. 1995.
68. Gasparro FP and Edelson RL. Extracorporeal Photochemotherapy. Photoimmunology. Jean Krutmann and Craig A. Elmetts, Eds. 17:231-245, 1995.
69. Heald, PW, Shapiro PE, Madison JF, Leboit PE, Edelson R. Cutaneous T-Cell Lymphoma: Relevant Scientific Summary of Neoplastic T-Cells: Classic Disease Description and Pathology. Cutaneous Medicine and Surgery, Kenneth Arndt, Philip LeBoit, June Robinson, and Bruce U. Wintroub, Eds. 158:1639-1659, 1995.
70. Lim H, Edelson RL. Photopheresis for the Treatment of Cutaneous T-cell Lymphoma. Monograph. Hematol Oncol Clin North Am Howard K. Koh, Francine M. Foss, Guest Editors. Vol. 9(5) 1117-26, 1995.
71. Edelson RL. Extracorporeal Photochemotherapy: Cellular Therapy for Cutaneous T-Cell Lymphoma, Selected Autoimmune Disorders, and Organ Transplant Rejection. Therapeutic Immunology edited by Drs. Austen, Burakoff, Rosen and Strom. Chapter 50:615-627, 1996.
72. Wilson LD, Kacinski BM, Edelson RL, Heald PW. Cutaneous T-Cell Lymphomas Cancer: Principles & Practice of Oncology edited by Vincent T. DeVita, Jr., MD, Samuel Hellman, MD, Steven A. Rosenberg, MD, PhD. Chapter 44(4):2220-2232, 1997.
73. Bologna JL, Edelson RL. Spread of antibiotic-resistant bacteria from acne patients to personal contacts - a problem beyond the skin? The Lancet editorial, David Frankel Editor. 350:972-973, 1997.
74. Edelson R.L. Cutaneous Allergy. N Engl J Med. 337:504, 1997.
75. Edelson RL and Berger C. Extracorporeal photochemotherapy. In: Malignant Tumors of the Skin. Chu AC and Edelson RL, eds. Edward Arnold Publishers Limited, London, England, pp. 396-408, 1999.
76. Heald PW and Edelson RL. Cutaneous T Cell Lymphoma. In: Malignant Tumors of the Skin. Chu AC and Edelson RL, eds. Edward Arnold Publishers, London, pp. 138-145, 1999.

77. Berger CL, Mariwalla K, Girardi M, Edelson RL. Advances in understanding the immunobiology and immunotherapy of cutaneous T cell lymphoma. In *Advances in Dermatology*, Volume 20, Chapter 8, pp. 217-235, 2005.
78. Berger CL, Shofner J, Vasquez JG, Mariwalla K and Edelson RL. Cancer Immunotherapy. *Cancer Therapy* Vol. 3, pp 1-17, 2005
79. Berger CL, Edelson R. Dendritic cell immunotherapy in malignancies. *Drugs of the Future* 2007, 32: 1-9.
80. Shofner JD, Vasquez JG, Berger CL, Edelson RL. Improved generation of anti-tumor immunity by antigen dose limitation. *J Immune Based Ther Vaccines* 5:2: doi: 10.11186/1476-8518, 2007.
81. Berger CL, Heald P, Edelson R: Cutaneous T cell lymphoma: advances in immunology translate into clinical practice. Chapter, *Immunobiology of the skin*. Sem Saeland Ed. (in press) 2008
82. Berger CL, Heald P, Girardi M, Edelson RL: Cutaneous T cell lymphoma: Translating immunobiology into therapeutic opportunities. *Gital Dermatol Venereol* 2008: 143-43-54.
83. Berger CL, Edelson R. Cancer immunotherapy: from promise to practice. *Drugs of the Future* 2008, 33(5):

#### Books

- Milstone L and Edelson R. Endocrine metabolic and immunologic functions of keratinocytes. *Annals NY Acad Science*, Volume 548, 1988.
- Edelson R. *Antigen and Clone-Specific Immunoregulation*. Editor, *Annals NY Acad Science*, Volume 636, 1991.
- A.C. Chu and R.L. Edelson. *Malignant Tumors of the Skin*. Editors. Edward Arnold Publishers Limited, London, England, 1999.
- Edelson Richard L. and DeVita, Jr., Vincent T. *Cutaneous T Cell Lymphoma*. Editor, *Annals NY Acad Science*, Volume 941, 2001.
- Edelson, Richard L. Editor, *Transfusion and Apheresis Science*. Vol. 26 Issue 3, June 2002.

#### Patents

1. 6,355,238, March 12, 2002, Specific immune system modulation, Edelson, Richard L., Westport, Connecticut Gasparro, Francis P., Hamden, Connecticut Tigelaar, Robert E., Guilford, Connecticut, Yale University, New Haven, Connecticut [02] United States Company or Corporation
2. 5,820,872, Oct.13, 1998, Methods and compositions for improving the effectiveness of X-irradiation therapy for the treatment of an internal solid tumor, Edelson, Richard L., Westport, Connecticut Gasparro, Francis P., Hamden, Connecticut, Yale University, New Haven, Connecticut (02)
3. 5,651,993, Jul. 29, 1997, Specific immune system modulation, Edelson, Richard L., Westport, Connecticut Gasparro, Francis P., Hamden, Connecticut Tigelaar, Robert E., Guilford,

Connecticut, Yale University, New Haven, Connecticut (02)

4. 5,462,733, Oct. 31, 1995, Immune system modulation using psoralens activated with visible light, Edelson, Richard L., Westport, Connecticut Gasparro, Francis P., Hamden, Connecticut, Yale University, New Haven, Connecticut (02)
5. 5,383,847, Jan. 24, 1995, Non-specific immune system enhancement, Edelson, Richard L., Westport, Connecticut, Therakos, Inc., West Chester, Pennsylvania (02)
6. 5,256,648, Oct. 26, 1993, Selective inhibition of gene expression by photoactivatable oligonucleotides, Gasparro, Francis P., Hamden, Connecticut, Edelson, Richard L., Westport, Connecticut, Yale University, New Haven, Connecticut (02)
7. 5,147,289, Sep. 15, 1992, Non-specific immune system enhancement, Edelson, Richard L., Westport, Connecticut, Therakos, Inc., West Chester, Pennsylvania (02)
8. 5,114,721, May 19, 1992, Preparation of T-cell and T-cell membrane for use in prevention and treatment of autoimmune diseases, Cohen, Irun R., Rehovot, Israel Shinitzky, Meir, Rehovot, Connecticut, Israel Edelson, Richard L., Westport, Connecticut, Yeda Research and Development Co. Ltd., Rehovot, Israel (03)
9. 4,868,311, Sep. 19, 1989, Biotinylated psoralens, Saffran, Wilma A., Forest Hills, New York Edelson, Richard L., Westport, Connecticut, Gasparro, Francis P., Hamden, Connecticut, Welsh, John T., New York, New York Cantor, Charles R., New York, New York, The Trustees of Columbia University in the City of New York, New York, New York (02)
10. 4,838,852, Jun. 13, 1989, Active specific immune suppression, Edelson, Richard L., Westport, Connecticut Tripodi, Daniel J., Lebanon, New Jersey, Therakos, Inc., Westchester, Pennsylvania (02)
11. 4,684,521, Aug. 4, 1987, Method and system for externally treating the blood, Edelson, Richard L., 3 Rall Ct., Roseland, New Jersey 07068, Bourke, Jr.; Frederic A., East Norwalk, Connecticut (04) , Bourke; Eleanor F., East Norwalk, Connecticut (04) , Edelson; Richard L., East Norwalk, Connecticut (04)
12. 4,683,889, Aug. 4, 1987, Method and system for externally treating the blood, Edelson, Richard L., 3 Rall Ct., Roseland, New Jersey 07068, Bourke, Jr.; Frederic A., East Norwalk, Connecticut (04), Bourke; Eleanor F., East Norwalk, Connecticut (04) , Edelson; Richard L., East Norwalk, Connecticut (04) , The Edelson Trust, East Norwalk, Connecticut (03)
13. 4,613,322, Sep. 23, 1986, Method and system for externally treating the blood, Edelson, Richard L., 3 Rall Ct., Roseland, New Jersey 07068
14. 4,612,007, Sep. 16, 1986, Method and system for externally treating the blood, Edelson, Richard L., 3 Rall Ct., Roseland, New Jersey 07068
15. 4,464,166, Aug. 7, 1984, Method for externally treating the blood, Edelson, Richard L., Roseland, New York, Bourke, Jr.; Frederic A., East Norwalk, Connecticut (04), Bourke; Eleanor F., East Norwalk, Connecticut (04) , Edelson; Richard L., East Norwalk, Connecticut (04), The Edelson Trust, East Norwalk, Connecticut (02)
16. 4,428,744, Jan. 31, 1984, Method and system for externally treating the blood, Edelson, Richard

L., Roseland, New Jersey, Bourke, Jr.; Frederic A., East Norwalk, Connecticut (04), Bourke; Eleanor F., East Norwalk, Connecticut (04), Edelson; Richard L., East Norwalk, Connecticut (04), The Edelson Trust, East Norwalk, Connecticut (02)

17. 4,398,906, Aug. 16, 1983, Method for externally treating the blood, Edelson, Richard L., 3 Rall Ct., Roseland, New York 07068, Bourke, Jr.; Frederic A., East Norwalk, Connecticut (04), Bourke; Eleanor F., East Norwalk, Connecticut (04), Edelson; Richard L., East Norwalk, Connecticut (04), The Edelson Trust, East Norwalk, Connecticut (02)
18. 4,321,919, Mar. 30, 1982, Method and system for externally treating human blood, Edelson, Richard L., Roseland, New Jersey, Leukocyte Research, Inc., Detroit, Michigan (02), Date Transaction Recorded: Oct. 29, 1982 CONDITIONAL ASSIGNMENT (SEE DOCUMENT FOR DETAILS). BOURKE, FREDERIC A., JR., BOURKE, ELEANOR F. EDELSON, RICHARD L. EDELSON, RUTH C. Reel & Frame Number: 4058/0043
19. 20010053355, December 20, 2001, Methods for inducing the differentiation of monocytes into functional dendritic cells, Edelson, Richard Leslie, Westport, Connecticut, United States (US)
20. 20020004044, January 10, 2002, Methods for inducing the differentiation of monocytes into functional dendritic cells, Edelson, Richard Leslie, Westport, Connecticut, United States [US]